Cardiovascular Disease (CVD) and the Role of Agent Alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production
Curator and Investigator Initiated Study: Aviva Lev-Ari, PhD, RN
Low HDL levels predict an increased risk of coronary artery disease independently of LDL levels, and 60–70% of major cardiovascular events cannot be prevented with current approaches focused on LDL, such as statin therapy (Werner et al., 2003), (Vasa et al., 2001a), (Walter et al., 2002), (Dimmeler et al., 2001), (Llevadot et al., 2001), (Spyridopoulos et al., 2004). In addition, low HDL levels are particularly common in males with early-onset atherosclerosis (Wilson et al., 1988). Based on these observations, prevention trials have been performed with agents such as niacin and fibrates, which raise HDL, and they indicate that modest increases in HDL independently yield a significant reduction in cardiovascular events (Rubins et al., 1999), (Brown et al., 2001), (Boden, 2000). Thus, there is compelling evidence that HDL is not solely a marker of lower risk of cardiovascular disease but instead is a mediator of vascular health.
Genistein – Phytoestrogens have received widespread attention over the past few years because of their potential for preventing some highly prevalent chronic diseases, including cardiovascular disease, osteoporosis, and hormone-related cancers. Genistein, the primary soy-derived phytoestrogen, has various biological actions (Liu et al., 2004), including a weak estrogenic effect and inhibition of tyrosine kinases. Genistein acutely stimulates Nitric Oxide synthesis in vascular Eendothelial cells by a cyclic adenosine 5′-monophosphate-dependent mechanism (Liu et al., 2004). The intracellular signaling pathways for activation of eNOS by genistein were independent of PI3K/Akt or ERK/MAPK but depended on the cAMP/PKA cascade. In addition, the genistein action on eNOS was not inhibited by an ER antagonist and was unrelated to tyrosine kinase inhibition.
Studies demonstrate that genistein has antiatherogenic effects and inhibits proliferation of vascular endothelial and smooth muscle cells. Data from animal and in vitro studies suggest a protective role of genistein in the vasculature. Studies investigating its effect on plasma lipid profiles show either a moderate positive effect or a neutral effect. Some human intervention studies suggest a beneficial effect on atherosclerosis (Anthony et al., 1998), markers of cardiovascular risk (van der Schouw et al., 2000), vasomotor tone (Walker et al., 2001), vascular endothelial function (Squadrito et al., 2003), and systemic arterial compliance (Nestel et al., 1997). Genistein also inhibits human platelet aggregation in vitro (Dobrydneva et al., 2002), (Gottstein et al., 2003) and decreases TNF-induced monocyte chemoattractant protein-1 secretion in human vascular endothelial cells (Gottstein et al., 2003). Other studies suggest that genistein may induce vascular relaxation by cAMP-dependent mechanisms (Satake and Shibata, 1999) or inhibition of tyrosine kinases (Duarte et al., 1997). In vitro studies elucidating the cellular or molecular mechanisms of the genistein action on vascular cells are lacking.
NO produced is a potent vasodilator and also has anti-inflammatory (Yu et al., 2002), antiatherogenic (Shin et al., 1996), antithrombotic (Alonso and Radomski, 2003), and antiapoptotic properties (Kotamraju, 2001). Liu et al., (2004), hypothesized that genistein directly regulates vascular function through stimulation of eNOS and NO synthesis from vascular endothelial cells. To test this hypothesis, they focused on the acute effects of genistein on eNOS and the cellular signaling related to this effect. They specifically tested the protein kinase A and tyrosine kinase pathways because these have been proposed in previous vascular studies (Satake and Shibata, 1999), (Duarte et al., 1997).
In Liu et al., (2004) study, genistein acted directly on BAECs and HUVECs to activate eNOS and NO production through nongenomic mechanisms in whole vascular endothelial cells. The intracellular signaling pathways for activation of eNOS by genistein were independent of PI3K/Akt or ERK/MAPK but depended on the cAMP/PKA cascade. In addition, the genistein action on eNOS was not inhibited by an ER antagonist and was unrelated to tyrosine kinase inhibition. The findings suggest a molecular mechanism that may underlie some of the beneficial cardiovascular effects that have been proposed for genistein.
Agent Alternative #2: Serotonin, 5-HT
5-hydroxytryptamine evokes endothelial nitric oxide synthase activation
eNOS activation in microvascular endothelial bEnd.3 cell. NO plays an important role in the dynamic regulation of the intercellular junctions of the endothelium. They have shown that eNOS is enriched at these junctions, which is a prerequisite for its activation by agonists. At the junctions, eNOS co-localizes with PECAM-1, but not with VE-cadherin and plakoglobin. The nature of the molecular mechanisms that lead to the enrichment of eNOS at intercellular junctions, and which allow these junctions to be regulated by NO, remains to be determined. Data from three experiments are presented as means±S.D. ‘D’ represents l-NAME-dependent (i.e. NOS-mediated) nitrite formation (Grovers et al., 2002).
Comparative analysis of eNOS efficacy on NO production. 5-HT is second in effectiveness.
Agonist Nitrite (nmol·mg of protein-1) -l-NAME +l-NAME D None 0.31±0.05 0.08±0.05 0.23±0.07
A23187 (5µM) 1.44±0.06 0.35±0.06* 1.09±0.08†
Acetylcholine (1µM) 0.83±0.12 0.06±0.09 0.77±0.15†
5-Hydroxytryptamine (1µM) 0.94±0.07 0.05±0.05 0.88±0.08†
VEGF (20ng/ml) 0.60±0.03 0.10±0.03 0.50±0.05†
Bradykinin (1µM) 0.28±0.06 0.04±0.05 0.24±0.07
Histamine (10µM) 0.36±0.04 0.08±0.05 0.28±0.06
Activation of endothelial nitric oxide synthase (eNOS) resulted in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells. The goal of this project was to address the possibility that 5-hydroxytryptamine (5-HT) stimulates eNOS activity in bovine aortic endothelial cell (BAEC) cultures. McDuffie et al., (1999, 2000) tested the hypothesis that 5-HT receptors mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures. They found that 5-HT stimulated the conversion of [3H]L- arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation. The high affinity 5-HT1B receptor agonist, 5-nonyloxytryptamine (5-NOT)- stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent. Maximal responses were observed within 10 min following agonist exposures. These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO). Their findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of eNOS by 5-HT.
3 orpholinosyndnonimine inhibits 5-hydroxytryptamine induced phosphorylation of nitric oxide synthase in endothelial cells.
5-Hydroxytryptamine (5-HT) is a vasoactive substance that is taken up by endothelial cells to activate endothelial nitrite oxide synthase (eNOS). The activation of eNOS results in the production of nitric oxide (NO), which is responsible for vasodilation of blood vessels. NO also interacts with superoxide anion (O2*-) to form peroxynitrite (ONOO-), a potent oxidant that has been shown to induce vascular endothelial dysfunction (Richardson et al., 2003). They examined the ability of 3-morpholinosyndnonimine (SIN-1), an ONOO- generator, to inhibit 5-HT-induced phosphorylation of eNOS in cultured bovine aortic endothelial cells (BAECs). They observed that 5-HT phosphorylates Ser1179 eNOS in a time- and concentration-dependent manner. Maximum phosphorylation occurred at 30 sec using a concentration of 1.0 microM 5-HT. BAECs treated with SIN-1 (1-1000 microM) for 30 min showed no significant increase in eNOS phosphorylation. However, 5-HT-induced eNOS phosphorylation was inhibited in cells treated with various concentrations of SIN-1 for 30 min and stimulated with 5-HT. These data suggest that an increase in ONOO- as a result of an increase in the production of O2*-, may feedback to inhibit 5-HT-induced eNOS phosphorylation at Ser1179 and therefore, contribute to endothelial dysfunction associated with cardiovascular diseases.
Agent Alternative #3: Nebivolol
A Third-Generation ß-Blocker that Augments Vascular Nitric Oxide Release. (Broeders et al., 2000), (Brugada et al., 2001), (Dessy et al., 2005), (Iaccarino et al., 2002), (Jordan et al., 2001), (Kalinowski et al., 2003), (Mason et al., 2005), (McEniery et al., 2004), (Mollnau et al., 2003), (Mukherjee et al., 2004), (Ritter et al., 2006).
In vivo metabolized nebivolol increases vascular NO production. This phenomenon involves endothelial ß2-adrenergic receptor ligation, with a subsequent rise in endothelial free [Ca2+]i and endothelial NO synthase–dependent NO production. This may be an important mechanism underlying the nebivolol-induced, NO-mediated arterial dilation in humans. Nebivolol is a ß1-selective adrenergic receptor antagonist with proposed nitric oxide (NO)–mediated vasodilating properties in humans. In this study, they explored whether nebivolol indeed induces NO production and, if so, by what mechanism. they hypothesized that not nebivolol itself but rather its metabolites augment NO production (Broeders et al., 2000).
Dose and Time Concentration for Agents affecting endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production
- time concentration dependence on eNOS reuptake
- dose concentration dependence on NO production
In the literature we found evidence for dose concentration dependence manner
Ach, Histamine, Genistein, ACEI, Fenofibrates, NEBIVOLOL, Calcium channel blocker, Enzyme S-nitrosylation
In the literature we found evidence for time concentration dependence manner:
Ach, BRL37344, a 3-adrenoceptor agonist
In the literature we found evidence for time and dose concentration dependence manner:
Histamine
| NO, eNOS AgonistsStimulate phosphorylation of eNOS at serine 1177, 1179, 116 Conversion of L-arginine toL-citrulline |
time concentration dependence manner |
dose concentration dependencemanner |
time and dose |
dose (nmol·mg of protein-1)Grovers et al., (2002) |
| A23187 |
|
|
|
(5µM) |
| Acetylcholine |
Xu et al., (2002) |
Sanchez et al., (2006) |
|
(1µM) |
| 5-Hydroxytryptamine |
|
|
|
(1µM) |
| VEGF ( |
|
|
|
(20ng/ml) |
| Bradykinin |
|
|
|
(1µM) |
| Histamine |
|
McDuffie et al., (1999) |
McDuffie et al., (2000) |
(10µM) |
| genistein |
|
Liu et al., (2004) |
|
(1µM) |
| ACEI |
|
Skidgel et al., (2006) |
|
|
| Fenofibrates |
|
Asai et al., (2006) |
|
|
| BRL37344, a 3-adrenoceptor agonist |
Pott et al., (2005) |
|
|
|
| NEBIVOLOLß1-selective adrenergic receptor antagonist with nitric oxide (NO)–mediation for vasodilation |
|
Ritter et al., (2006) |
|
|
| Calcium channel blocker |
|
Church and Fulton, (2006), |
|
|
| Enzyme S-nitrosylation |
|
Erwin et al., (2006) |
|
|
Proposed integration plan of Nebivolol with CVD patients’ current medication regimen for selective medical diagnoses
Blood Pressure Medicine:
Beta blockers, Verapamil (Calan), Reserpine (Hydropes), Clonidine (Catapres), Methyldopa (Aldomet)
Diuretics:
Thiazides, Spironolactone (Aldactone), Hydralazine
Antidepressants:
Prozac, Lithium, MOA’s, Tricyclics
Stomach Medicine:
Tagamet and Zantac, plus other compounds containing Cimetidine and Ranitidine or associated compounds in Anticholesterol Drugs
Antipsychotics:
Chlorpromazine (Thorazine), Pimozide (Orap), Thiothixine (Navane), Thiordazine (Mellaril), Sulpiride, Haloperidol (haldol), Fluphenazine (Modecate, Prolixin)
Heart Medicine:
Clofibrate (Atromid), Gemfibrozil, Diagoxin
Hormones:
Estrogen, Progesterone, Proscar, Casodex, Eulexin, Corticosteroids Gonadotropin releasing antagonists: Zoladex and Lupron
Cytotoxic agents:
Cyclophosphamide, Methotrexate, Roferon Non-steroidal anti-inflammatories
Others-
Alprazolam, Amoxapine, Chlordiazepoxide, Sertraline, Paroxetine, Clomipramine, Fluvoxamine, Fluoxetine, Imipramine, Doxepine, Desipramine, Clorprothixine, Bethanidine, Naproxen, Nortriptyline, Thioridazine, Tranylcypromine, Venlafaxine, Citalopram.
INTERACTIONS for Nebivolol
Calcium Antagonists:
Caution should be exercised when administering beta-blockers with calcium antagonists of the verapamil or diltiazem type because of their negative effect on contractility and atrio-ventricular conduction. Exaggeration of these effects can occur particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities. Neither medicine should therefore be administered intravenously within 48 hours of discontinuing the other.
Anti-arrhythmics:
Caution should be exercised when administering beta-blockers with Class I anti-arrhythmic drugs and amiodarone as their effect on atrial conduction time and their negative inotropic effect may be potentiated. Such interactions can have life threatening consequences.
Clonidine:
Beta-blockers increase the risk of rebound hypertension after sudden withdrawal of chronic clonidine treatment.
Digitalis:
Digitalis glycosides associated with beta-blockers may increase atrio-ventricular conduction times. Nebivolol does not influence the kinetics of digoxin & clinical trials have not shown any evidence of an interaction.
Special note: Digitalisation of patients receiving long term beta-blocker therapy may be necessary if congestive cardiac failure is likely to develop. The combination can be considered despite the potentiation of the negative chronotropic effect of the two medicines. Careful control of dosages and of individual patient’s response (notably pulse rate) is essential in this situation.
Insulin & Oral Antidiabetic drugs:
Glucose levels are unaffected, however symptoms of hypoglycemia may be masked.
Anaesthetics:
Concomitant use of beta-blockers & anaesthetics e.g. ether, cyclopropane & trichloroethylene may attenuate reflex tachycardia & increase the risk of hypotension
CVD patients’ current medication regimen for selective medical diagnoses
| Medical Diagnoses |
Current medication regiment |
eNOS agonists &production stimulation of NO |
PPAR-gamma agonist (TZD) as eNOS stimulant |
| CAD patients |
Beta blockers, ACEI, ARB, CCB, Diagoxin, Coumadin |
yes |
|
| Endothelial Dysfunction in DM patients with or without Erectile Dysfunction |
Insulin |
yes |
yes |
| Atherosclerosis patients: Arteries and or veins |
AntihypertensiveCoumadin |
yes |
yes |
| pre-stenting treatment phase |
Beta blockers, Verapamil (Calan), Reserpine (Hydropes), Clonidine (Catapres), Methyldopa (Aldomet) |
yes |
|
| post-stenting treatment phase |
Antiplatelets |
|
yes |
| if stent is a Bare Mesh stent (BMS) |
CoumadinBeta blockers |
|
yes |
| if stent is Drug Eluting stent (DES) |
antibiotics |
|
|
| if stent is EPC antibody coated |
|
|
yes |
| post CABG patients |
CoumadinBeta blockers, Verapamil (Calan), Reserpine (Hydropes), Clonidine (Catapres), Methyldopa (Aldomet) |
|
yes |
| CVD patients on blood thinner drugs |
Coumadin |
yes |
|
Conclusions
- Most favorable and unexpected to us was finding in the literature new indications for TDZs as stimulators of eNOS, in addition to the new indication for atherosclerosis besides the classic indication in pharmacology books, being in the reduction of insulin resistance.
- Most favorable and unexpected to us was finding in the literature new indications for beta blockers as NO stimulant, nebivolol, a case in point, thus, fulfilling two indications in one drug along the direction of the study to identify eNOS agonists. Nebivolol is a vasodilator, thus functions as an antihypertensive.
REFERENCES
Alonso DE, Radomski MW, (2003). Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev., 2003, 8:47–54.
Anthony MS, Clarkson TB, Williams JK, (1998). Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr., 68(6 Suppl):1390S–1393S.
Benowitz, NL., (2004). Antihypertensive Agents. Chapter 11 in Katzung, BG., Basic & Clinical Pharmacology. McGraw-Hill, 9th Edition, pp. 160-183.
Bisoendial RJ, et al. (2003). Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation, 107:2944–2948.
Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ., (1999). Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation.J. Biol. Chem., 274:32512–32519.
Brixius K, Song Q, Malick A, Boelck B, Addicks K, Bloch W, Mehlhorn U, Schwinger R, (2006). eNOS is not activated by nebivolol in human failing myocardium. Life Sci., 2006 Apr 25
Broeders MAW, Doevendans PA, Bekkers BCAM, Bronsaer R, van Gorsel E, Heemskerk JWM. oude Egbrink MGA, van Breda E, Reneman RS, van der Zee R, (2000). Nebivolol: A Third-Generation ß-Blocker That Augments Vascular Nitric Oxide Release, Endothelial ß2-Adrenergic Receptor–Mediated Nitric Oxide Production. Circulation, 102:677.
Brown BG, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 345:1583–1592.
Brugada P, Brugada J, Brugada R, (2001). Dealing with biological variation in the Brugada syndrome. Eur. Heart J., 22(24): 2231 – 2232.
Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR., (1997). 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ. Res., 81:885–892.
Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, and Fitzgerald GA., (2006). Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest., 116:1391-1399
Church JE, Fulton D., (2006). Differences in eNOS activity because of subcellular localization are dictated by phosphorylation state rather than the local calcium environment.J Biol Chem., 2006 Jan 20;281(3):1477-88. Epub 2005 Oct 28.
Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F, Belge C, Jnaoui K, Noirhomme P, Feron O, Balligand JL, (2005). Endothelial {beta}3-Adrenoreceptors Mediate Nitric Oxide-Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-Generation {beta}-Blocker Nebivolol. Circulation, 112(8): 1198 – 1205.
Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM, (2001). HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest., 108:391–397.
Dobrydneva Y, Williams RL, Morris GZ, Blackmore PF, (2002). Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets. J Cardiovasc Pharmacol, 40:399–410.
Duarte J, Ocete MA, Perez-Vizcaino F, Zarzuelo A, Tamargo J, (1997). Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. Eur J Pharmacol, 338:25–33.
Erwin PA, Mitchell DA, Sartoretto J, Marletta MA, Michel T., (2006). Subcellular Targeting and Differential S-Nitrosylation of Endothelial Nitric-oxide Synthase. J. Biol. Chem., 281:1, 151-157.
George T. and P. Ramwell, (2004). Nitric Oxide, Donors, & Inhibitors. Chapter 19 in Katzung, BG., Basic & Clinical Pharmacology. McGraw-Hill, 9th Edition, pp. 313 – 318.
Gong M, et al., (2003). HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner.J. Clin. Invest., 111:1579–1587.
Gonzalez E, Kou R, Lin AJ, Golan DE, Michel T., (2002). Subcellular Targeting and Agonist-induced Site-specific Phosphorylation of Endothelial Nitric-oxide Synthase. J. Biol. Chem., 277;42:39554-39560.
Goon, P.K.Y. Lip G.Y.H, Boos, CJ, Stonelake, PS, Blann, AD. (2006). Circulating Endothelial Cells, Endothelial Progenitor Cells, and Endothelial Microparticles in Cancer, Neoplasia, 8:79-88.
Gottstein N, Ewins BA, Eccleston C, Hubbard GP, Kavanagh IC, Minihane AM, Weinberg PD, Rimbach G, (2003). Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function. Br J Nutr, 89:607–616
Grovers R, Bevers L, De Bree P, Rabelink TJ, (2002). Endothelial nitric oxide synthase activity is linked to its presence at cell–cell contacts.Biochem. J., 361 (193–201) (Printed in Great Britain)
Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ, (1996). Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation, 15;93(10):1860-70.
Iaccarino G, Cipolletta E, Fiorillo A, AnnecchiaricoM, Ciccarelli M, Cimini V, Koch WJ, B. Trimarco B, (2002). {beta}2-Adrenergic Receptor Gene Delivery to the Endothelium Corrects Impaired Adrenergic Vasorelaxation in Hypertension. Circulation, 106(3): 349 – 355.
Jordan J, Tank J, Stoffels, Franke MG, Christensen NJ, Luft CF, Boschmann M, (2001). Interaction between {beta}-Adrenergic Receptor Stimulation and Nitric Oxide Release on Tissue Perfusion and Metabolism. J. Clin. Endocrinol. Metab., 86(6): 2803 – 2810.
Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski, T, (2003). Third-Generation {beta}-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux: A Novel Mechanism for Antihypertensive Action.Circulation. 2003 Jun 3;107(21):2747-52. Epub 2003 May 12.
Kleinman, ME, Blei, F, Gurtner, GC, (2005). Circulating Endothelial Progenitor Cells and Vascular Anomalies, Lymphatic Research and Biology, 3;4: 234-239.
Koshimizu T-A, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G., (2006). V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. PNAS, 103;20: 7807-7812.
Kotamraju S, Hogg N, Joseph J, Keefer LK, Kalyanaraman B, (2001). Inhibition of oxidized low-density lipoprotein-induced apoptosis in endothelial cells by nitric oxide. Peroxyl radical scavenging as an antiapoptotic mechanism. J Biol Chem, 276:17316–17323.
Kuvin JT, et al., (2002). A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J., 144:165–172.
Lahav R, Heffner G, Patterson PH., (1999). An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. PNAS, 96;20: 11496-11500.
Lantin-Hermoso RL, et al., (1997). Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am. J. Physiol., 273:L119–L126.
Laszlo, F, Whittle BJR, Moncada S., (1994). Time dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br. J. Pharmacol., 111, 1309–1315.
Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G, (2003). Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation, 109:220 –226.
Li AC, Binder, CJ, Gutierrez, A, Brown, KK, Plotkin, CR, Pattison, JW, Valledor, AF, Davis, RA, Willson, TM, Witztum, JL, Palinski, W, Glass, CK. (2004). Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR-alpha, Beta/delta, and gamma. J. Clin. Invest., 114:1564-1576.
Li XP, et al., (2000). Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int. J. Cardiol., 73:231–236.
Liu D, Homan LL, Joseph, Dillon JS., (2004). Genistein Acutely Stimulates Nitric Oxide Synthesis in Vascular Endothelial Cells by a Cyclic Adenosine 5′-Monophosphate-Dependent Mechanism, Endocrinology, 145:12, 5532-5539.
Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T, (2001). HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest., 108:399–405.
McDuffie JE, Coaxum SD, Maleque MA, (1999) 5-Hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures. Proceedings of the Society for Experimental Biology and Medicine, 221, 386-390.
McDuffie JE, Motley ED, Limbird LE, Maleque, MA, (2000). 5-Hydroxytryptamine Stimulates Phosphorylation of p44/p42 Mitogen-Activated Protein Kinase Activation in Bovine Aortic Endothelial Cell Cultures. Journal of Cardiovascular Pharmacology, 35(3):398-402.
McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, Cockcroft JR, (2004). Nebivolol Increases Arterial Distensibility In Vivo. Hypertension, 44(3): 305 – 310.
Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski BT, (2005). Nebivolol Reduces Nitroxidative Stress and Restores Nitric Oxide Bioavailability in Endothelium of Black Americans. Circulation, 112(24): 3795 – 3801.
Mineo C, Yuhanna IS, Quon MJ, Shaul PW., (2003). HDL-induced eNOS activation is mediated by Akt and MAP kinases. J. Biol. Chem., 278:9142–9149.
Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, Wendt M, Walter U, Geiger C, Agrawal R, Kleschyov AL, Meinertz T. Munzel T, (2003). Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells. Arterioscler. Thromb. Vasc. Biol., 23(4): 615 – 621.
Moncada S., (2005). Adventures in vascular biology: a tale of two mediators. Phil. Trans. R. Soc. B29 May 2006 vol. 361 no. 1469 735-759
Moncada S, and Higgs EA, (2006). The discovery of nitric oxide and its role in vascular biology. British Journal of Pharmacology, 147, S193–S201
Mukherjee S, Baksi S, Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH, (2003). {beta}-Blockers With Vasodilatory Actions. Chest, 124(4): 1621 – 1621.
Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, Hirai T, Numaguchi Y, Okumura K, Seo H, Murohara T., (2006). Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun., 341(4):973-8. Epub 2006 Jan 24.
Nebivolol is a long-acting, cardioselective beta-blocker currently licensed for the treatment of hypertension.
http://www.saha.org.ar/noticias/nebivolol2.htm – retrieved on 6/20/2006
Nebivolol
http://www.intekom.com/pharm/adcock/nebilet.html – retrieved on 6/20/2006
Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A, Abbey M, (1997). Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 17:3392–3398.
Nofer J-R, et al., (2004). HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest.,113:569–581.
Nolte MS and JH Karam, (2004). Pancreatic Hormones & Antidiabetic Drugs. Chapter 41 in Katzung, BG., Basic & Clinical Pharmacology. McGraw-Hill, 9th Edition, pp.693-715, in particular, Thiazolidinediones, pp.709-710, 713.
Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM, (2005). Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.Arterioscler Thromb Vasc Biol., 25(9):1810-6. Epub 2005 Jul 14.
Pott C, Steinritz D, Bölck B, Mehlhorn U, Brixius K, Schwinger RHG, BlochW., (2006). eNOS translocation but not eNOS phosphorylation is dependent on intracellular Ca2+ in human atrial myocardium. Am J Physiol Cell Physiol 290: C1437-C1445.
Ramet ME, et al., (2003). High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol., 41:2288–2297.
Reid, Ian A., (2004). Vasoactive Peptides. Chapter 17 in Katzung, BG., Basic & Clinical Pharmacology. McGraw-Hill, 9th Edition, pp. 281 – 297, in particular, Endothelins, pp. 290-293.
Richardson SM, Maleque MA, Motley ED., (2003). 3-Morpholinosyndnonimine inhibits 5-hydroxytryptamine-induced phosphorylation of nitric oxide synthase in endothelial cells. Cell Mol Biol., 49(8):1385-1389.
Ritter JM, Ferro A, Chowienczyk PJ., (2006). Relation between beta-adrenoceptor stimulation and nitric oxide synthesis in vascular control. Eur J Clin Pharmacol., 62 (Supplement 13):109-113.
Rosenzweig A., (2005). Circulating Endothelial Progenitors – Cells as Biomarkers. NEJM., 353;10: 1055-1057.
Rubins et al., (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med., 341:410–418.
Sanchez FA, Savalia NB, Duran RG, Lal BK, Boric MP, Duran WN., (2006). Functional significance of differential eNOS translocation. Am J Physiol Heart Circ Physiol., May 5; [Epub ahead of print]
Satake N, Shibata S, (1999). The potentiating effect of genistein on the relaxation induced by isoproterenol in rat aortic rings. Gen Pharmacol, 33:221–227.
Shaul PW., (2002). Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol., 64:749–774.
Shaul, PW and Mineo, C, (2004). HDL action on the vascular wall: is the answer NO? J Clin Invest., 15; 113(4): 509–513.
Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK, (1996). Nitric oxide attenuates vascular smooth muscle cell activation by interferon. The role of constitutive NF-B activity. J Biol Chem, 271:11317–11324.
Skidgel RA, Stanislavjevic S, Erdos EG., (2006). Kinin- and angiotensin-converting enzyme (ACE) inhibitor-mediated nitric oxide production in endothelial cells. Biol Chem., 387(2):159-65.
Spieker et al., (2002). High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation, 105:1399–1402.
Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, Dimmeler S, (2004). Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation, 110:3136 –3142.
Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, D’Anna R, Corrado F, Ruggeri P, Frisina N, Squadrito G, (2003). Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med, 114:470–476.
Sütsch G, Kiowski W, Yan X-W, Hunziker P, Christen S, Strobel W, Kim J-H, Rickenbacher P, Bertel O., (1998). Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. Circulation, 98:2262-2268
Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ., (2000). High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem., 275:11278–11283.
van der Schouw YT, de Kleijn MJ, Peeters PH, Grobbee DE, (2000). Phyto-oestrogens and cardiovascular disease risk. Nutr Metab Cardiovasc Dis., 10:154–167.
Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JI., (1997). A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens.,11(2):139-44.
Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, Dimmeler S. (2001a). Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation, 103:2885–2890.
Verma S, Szmitko, PE, (2006). The vascular biology of peroxisome proliferator-activated receptors: Modulation of atherosclerosis. Can J Cardiol, 22 (Suppl B):12B-17B.
Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ, (2001). The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17ß-estradiol. Circulation, 103:258–262.
Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM, (2002). Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation, 105:3017–3024.
Wang C-H, Ciliberti N, Li S-H, Szmitko PE, Weisel RD, Fedak PWM, Al-Omran M, Cherng W-J, Li R-K, Stanford WL, Verma S., (2004). Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation, 109:1392-1400.
Werner N, Junk S, Laufs L, Link A, Walenta K, Bohm M, Nickenig G., (2003). Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res., 93:e17– e24.
Werner N, Kosiol S, Tobias Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Georg N (2005). Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med 2005; 353:999-1007
Wilson PW, Abbott RD, Castelli WP, (1988). High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 8:737–741.
Xu H-L, Feinstein DL, Santizo RA, Koenig HM, Pelligrino DA., (2002).Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats. Am J Physiol Heart Circ Physiol., 282:H237-H243
Yu J, Rudic RD, Sessa WC, (2002). Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Lab Invest, 82:825–832.
Yuhanna IS, et al., (2001). High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med., 7:853–857.
Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H., (1994). Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation, 89:2525–2532.
Other aspects of Nitric Oxide involvement in biological systems in humans are covered in the following posts on this site:
Nitric Oxide in bone metabolism July 16, 2012
Author: Aviral Vatsa PhD, MBBS
http://pharmaceuticalintelligence.com/2012/07/16/nitric-oxide-in-bone-metabolism/?goback=%2Egde_4346921_member_134751669
Nitric Oxide production in Systemic sclerosis July 25, 2012
Curator: Aviral Vatsa, PhD, MBBS
http://pharmaceuticalintelligence.com/2012/07/25/nitric-oxide-production-in-systemic-sclerosis/?goback=%2Egde_4346921_member_138370383
Nitric Oxide Signalling Pathways August 22, 2012
Curator/ Author: Aviral Vatsa, PhD, MBBS
http://pharmaceuticalintelligence.com/2012/08/22/nitric-oxide-signalling-pathways/?goback=%2Egde_4346921_member_151245569
Nitric Oxide: a short historic perspective August 5, 2012
Author/Curator: Aviral Vatsa PhD, MBBS
http://pharmaceuticalintelligence.com/2012/08/05/nitric-oxide-a-short-historic-perspective-7/
Nitric Oxide: Chemistry and function August 10, 2012
Curator/Author: Aviral Vatsa PhD, MBBS
http://pharmaceuticalintelligence.com/2012/08/10/nitric-oxide-chemistry-and-function/?goback=%2Egde_4346921_member_145137865
Nitric Oxide and Platelet Aggregation August 16, 2012
Author: Dr. Venkat S. Karra, Ph.D.
http://www.tginnovations.wordpress.com/
http://pharmaceuticalintelligence.com/2012/08/16/no-and-platelet-aggregation/?goback=%2Egde_4346921_member_147475405
The rationale and use of inhaled NO in Pulmonary Artery Hypertension and Right Sided Heart Failure August 20, 2012
Author: Larry Bernstein, MD
http://pharmaceuticalintelligence.com/2012/08/20/the-rationale-and-use-of-inhaled-no-in-pulmonary-artery-hypertension-and-right-sided-heart-failure/
Nitric Oxide: The Nobel Prize in Physiology or Medicine 1998 Robert F. Furchgott, Louis J. Ignarro, Ferid Murad August 16, 2012
Reporter: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2012/08/16/nitric-oxide-the-nobel-prize-in-physiology-or-medicine-1998-robert-f-furchgott-louis-j-ignarro-ferid-murad/
Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents August 13, 2012
Author: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/
Nano-particles as Synthetic Platelets to Stop Internal Bleeding Resulting from Trauma
August 22, 2012
Reporter: Dr. V. S. Karra, Ph.D.
http://www.tginnovations.wordpress.com/
http://pharmaceuticalintelligence.com/2012/08/22/nano-particles-as-synthetic-platelets-to-stop-internal-bleeding-resulting-from-trauma/
Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production July 19, 2012
Curator and Investigator Initiated Study: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2012/07/19/cardiovascular-disease-cvd-and-the-role-of-agent-alternatives-in-endothelial-nitric-oxide-synthase-enos-activation-and-nitric-oxide-production/
Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk
An Investigation of the Potential of circulating Endothelial Progenitor Cells (cEPCs) as a Therapeutic Target for Pharmacological Therapy Design for Cardiovascular Risk Reduction: A New Multimarker Biomarker Discovery July 2, 2012
Curator: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2012/07/02/macrovascular-disease-therapeutic-potential-of-cepcs-reduction-methods-for-cv-risk/
Bone remodelling in a nutshell June 22, 2012
Author: Aviral Vatsa, Ph.D., MBBS
http://pharmaceuticalintelligence.com/2012/06/22/bone-remodelling-in-a-nutshell/
Read Full Post »
2012pharmaceutical
sjwilliamspa